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Abstract
Food-grade Lactic Acid Bacteria (LAB) have been safely consumed for centuries by humans in fermented foods.
Thus, they are good candidates to develop novel oral vectors, constituting attractive alternatives to attenuated
pathogens, for mucosal delivery strategies. Herein, this review summarizes our research, up until now, on the use
of LAB as mucosal delivery vectors for therapeutic proteins and DNA vaccines. Most of our work has been based
on the model LAB Lactococcus lactis, for which we have developed efficient genetic tools, including expression
signals and host strains, for the heterologous expression of therapeutic proteins such as antigens, cytokines and
enzymes. Resulting recombinant lactococci strains have been tested successfully for their prophylactic and
therapeutic effects in different animal models: i) against human papillomavirus type 16 (HPV-16)-induced tumors in
mice, ii) to partially prevent a bovine b-lactoglobulin (BLG)-allergic reaction in mice and iii) to regulate body weight
and food consumption in obese mice. Strikingly, all of these tools have been successfully transposed to the
Lactobacillus genus, in recent years, within our laboratory. Notably, anti-oxidative Lactobacillus casei strains were
constructed and tested in two chemically-induced colitis models. In parallel, we also developed a strategy based
on the use of L. lactis to deliver DNA at the mucosal level, and were able to show that L. lactis is able to modulate
the host response through DNA delivery. Today, we consider that all of our consistent data, together with those
obtained by other groups, demonstrate and reinforce the interest of using LAB, particularly lactococci and
lactobacilli strains, to develop novel therapeutic protein mucosal delivery vectors which should be tested now in
human clinical trials.
Introduction
The administration of therapeutic molecules via mucosal
routes offers several important advantages over systemic
delivery such as reduction of secondary effects, easy
administration and the possibility to modulate both sys-
temic and mucosal immune responses [1]. Moreover,
direct delivery of the appropriate medical molecules to
exert their effects at mucosal surfaces is a very efficient
prophylactic and therapeutic strategy. Mucosal surfaces
are the primary interaction sites between an organism and
its environment and they thus represent the major portal
of entry for pathogens. In the last fifteen years, there have
been several reports of successful immunisation with a
variety of mucosal vector vaccines [2]. They can induce
efficient systemic immune respo n s e sw i t hl e s sc o l l a t e r a l
side effects than systemic vaccines [1]. Additionally, muco-
sal immunisation is more easily performed, without the
need for needles and syringes, thereby eliminating the
requirement for trained personnel (important feature for
mass vaccination programs) [3]. Nevertheless, a major dis-
advantage is that a large amount of protein needs to be
administered, due to the fact that the majority of protein
will degrade, with very small quantities surviving degrada-
tion at mucosal surfaces such as the gastro intestinal tract
[1]. Therefore, the development of new vectors, able to
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technological challenge.
Today, sufficient data is available supporting the fact
that lactic acid bacteria (LAB), notably lactococci and lac-
tobacilli, are excellent candidates as delivery vectors of
therapeutic proteins, in the development of novel preven-
tive and therapeutic strategies for humans. LAB are non-
pathogenic Gram-positive bacteria and they have an
extraordinary safety profile, since they have been widely
consumed for centuries by humans in fermented foods.
Therefore, they constitute an attractive alternative to
attenuated pathogens, which are the most popular live
vectors being used currently. Attenuated pathogenic bac-
teria, such as derivatives of Mycobacterium, Salmonella,
and Bordetella spp. are particularly well adapted to inter-
act with mucosal surfaces as most of them they normally
use to initiate the infection process. Unfortunately, these
bacteria can recover their pathogenic potential and are
therefore not entirely safe for use in humans, especially
in children and immunosuppressed patients. Several
detailed reviews of vector delivery strategies, based on
LAB, have been published within the last five years, of
which three are particularly exhaustive and convincing
[4-6]. Herein, we will be summarizing our current
research and advances on the use of lactococci and lacto-
bacilli as live delivery vectors of proteins with health
interest. We will also be describing the use of LAB as
DNA-vaccine-delivery vehicles to deliver DNA directly to
antigen-presenting cells of the immune system.
1. Lactic acid bacteria as mucosal delivery vectors of
antigens and cytokines
The immunogenicity of soluble proteins administered
orally or intranasally is generally low and can be signifi-
cantly enhanced by either coupling the protein to a bacter-
ial carrier or by genetic engineering of bacteria resulting in
the production of the desired antigen. As previously
mentioned, food-grade or commensal Gram-positive bac-
teria constitute an attractive alternative to attenuated
pathogenic bacteria [6]. In particular, the model LAB
Lactococcus lactis and certain species of lactobacilli pos-
sess a number of properties, making them attractive candi-
dates for the development of mucosal vaccines [7].
Moreover, many antigens and/or cytokines have been
successfully expressed in LAB, and mucosal administration
of these genetically engineered LAB has been shown to eli-
cit both systemic and mucosal immunity (see additional
file 1).
The production of a desired antigen by LAB can occur
in three different cellular locations: i) intracellular,
which allows the protein to escape harsh external envir-
onmental conditions (such as gastric juices in the
stomach after oral administration of the recombinant
strain) but requires cellular lysis for protein release and
delivery, ii) extracellular, which allows the release of the
protein into the external medium, resulting in direct
interaction with the environment (food product or the
digestive tract), and iii) cell wall-anchored, which com-
bines the advantages of the other two locations (i.e.,
interaction between the cell wall-anchored protein and
the environment, in addition to protection from proteo-
lytic degradation). In this context, several studies have
compared the production of different antigens in LAB,
using all three locations and evaluated the subsequent
immunological impact [Reviewed in Refs. [6] and [7]].
Even if the comparison between the localization is diffi-
cult due to the amount of protein depending on the
localization, these studies demonstrated that the highest
immune response was usually obtained with cell-wall
anchored antigens exposed to the surface of LAB.
Therefore, most of the recent LAB vaccination studies
have selected surface exposure of the antigen of interest,
rather than intra- or extracellular production.
Lactococcus lactis as live delivery vector of proteins of
health interest
L. lactis is the most widely used LAB in the production of
fermented milk products, and is considered as the model
LAB because many genetic tools have been developed in
particular for heterologous protein production [8]. More-
over, L. lactis is considered to be a good candidate for
heterologous protein production because it secretes rela-
tively few proteins and only one, Usp45, in detectable
quantities [9,10]. In addition, the most commonly used
laboratory L. lactis strain (MG1363) is plasmid-free and
does not produce any extracellular proteases [11]. How-
ever, the major advantage of using L. lactis as a live vector
for mucosal delivery of therapeutic proteins resides in its
extraordinary safety profile, since this bacterium is catalo-
gued as a non-invasive and non-pathogenic organism with
a GRAS status. Finally, the capacity of L. lactis to produce
many different proteins of health interest has been clearly
demonstrated in the last two decades (see additional file
1). All of these features explain why most of the relevant
studies focusing on the use of LAB as protein and DNA
delivery vectors have been performed with L. lactis.
Heterologous proteins production in L. lactis
Currently, several inducible and constitutive expression
signals are available for L. lactis[2][3,6]. In our studies,
we mainly used the nisin inducible promoter (PnisA),
which is the major element of the NICE (Nisin Induced
Controlled Expression) system [12]. Nisin is a bacteriocin
produced by L. lactis, which contains eleven adjacent
chromosomal genes (nisABTCIPRKFEG) encoding for
biosynthesis and immunity against nisin [13]. The nisA
gene encodes for the structural nisin gene, whereas nisRK
encode for the dual-component system responsible for
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genes of interest were cloned downstream of PnisA and
the resulting plasmid was introduced in L. lactis NZ9000
(MG1363 strain carrying nisRK genes on its chromo-
some). Addition of sub-inhibitor nisin concentration
levels, into the culture medium, induces the expression
of the gene of interest proportionally to the dose of nisin
used. This system is now considered as the most efficient
one for heterologous expression in L. lactis[14]. We have
thus developed an efficient heterologous protein produc-
tion-secretion system in L. lactis based on PnisA and a
small stable and well-characterized protein, Staphylococ-
cus aureus nuclease (Nuc) [15].
A family of three expression vectors: pCYT, pSEC, and
pCWA was developed, to allow protein targeting to be
either intracellular, secreted, or cell wall anchored, respec-
tively. We also constructed a fourth expression vector
called pSEC:LEISS, which contains a synthetic propeptide
(LEISSTCDA) identified as a production-secretion booster
[16]. These vectors, also functional in several other LAB
species including lactobacilli, streptococci, enterococci and
bifidobacteria, have been successfully used to produce
approximately 50 different heterologous proteins in
L. lactis up to date (see additional file 1). More recently,
we also developed a new bile salts-inducible promoter,
which is currently being tested in in vivo experiments
(data not shown). Concerning the possible host factors
affecting production-secretion in L. lactis, we have identi-
fied ybdD which, once inactivated, induces an overproduc-
tion of secreted protein [Morello et al., unpublished data].
In addition, the secretion machinery for L. lactis has also
been complemented with B. subtilis SecDF, which induced
an increase in both production and secretion rates [17].
Within our panel of L. lactis strains, we also have three
mutants: one inactivated in the unique extracellular
housekeeping protease HtrA [18], one inactivated in the
major intracellular protease ClpP, and one inactivated in
both HtrA and Clp [19]. These strains are essential to
reach controlled and stable production of highly degraded
proteins in the wild type L. lactis strain [20].
2. Use of recombinant lactococcci to induce mucosal and
systemic immune responses against bacterial and viral
pathogens
Currently, a number of studies support the use of recom-
binant L. lactis to induce mucosal and systemic immune
responses against a desired antigen [2,7]. In 1990, the first
attempt to use L. lactis as a mucosal vaccine was per-
formed with killed recombinant lactococci producing a
cell wall-attached form of a Streptococcus mutans protec-
tive antigen (PAc). Mice immunized orally with this killed
L. lactis recombinant strain developed PAc-specific serum
IgG and mucosal IgA antibodies [21]. These results
demonstrated, for the first time, that L. lactis can
efficiently present an antigen to the immune system. In
1993, Wells et al. [22] then reported, for the first time, of
the use of live recombinant L. lactis, producing tetanus
fragment C (TTFC), to protect mice via subcutaneous
injection against a lethal challenge with tetanus toxin.
Afterwards, the same group evaluated the effect of immu-
nization route (oral or nasal administration) on live
recombinant lactococci producing TTFC in mice [23,24].
Oral immunization in mice resulted in a lower serum IgG
and mucosal IgA antibody response as compared to nasal
immunisation; whereas the protective efficacy (i.e. chal-
lenge with tetanus toxin) was similar between both routes.
Many studies have been conducted to analyze the expres-
sion of viral, bacterial or eukaryotic heterologous proteins
in L. lactis (see additional file 1).
The immunogenicity of the resulting recombinant
strains has been evaluated, in mouse models in some
cases, with very promising results. Amongst them, one of
the best documented projects is based on the use of
recombinant L. lactis producing human papillomavirus
type 16 (HPV-16) E7 antigen. This viral protein is consid-
ered as a major candidate antigen for vaccines against
HPV-related cervical cancer, the second cause of cancer
death in women. The intracellular production of E7 anti-
gen led to its rapid degradation in the cytoplasm of
L. lactis, even when produced in a protease-free clpP strain
[25]. In contrast, secreted and cell wall-anchored forms are
rescued from proteolysis and produced a higher level of E7
in L. lactis[25,26]. Antigen-specific humoral (production of
E7 antibodies) and cellular (secretion of IL-2 and IFN-g
cytokines) responses were observed after intranasal admin-
istration of recombinant lactococci expressing E7 antigen
at different levels and in cellular locations to mice. The
responses were significantly higher in mice immunized
with L. lactis expressing E7 as a cell wall-anchored form
[27]. Subsequently, the protective effect of mucosally co-
administered live L. lactis strains expressing cell wall-
anchored E7 and a secreted form of interleukin-12 to treat
HPV-16-induced tumors in a murine model was then
evaluated [28]. When challenged with lethal levels of
tumor cell line TC-1 expressing E7, 50% of pre-treated
mice demonstrated complete prevention of TC-1-induced
tumors. Therapeutic immunization with these recombi-
nant strains, (i.e., 7 days after TC-1 injection) induced
regression of palpable tumors in 35% of treated mice.
These preclinical results suggest the feasibility of mucosal
vaccination and/or immunotherapy against HPV-related
cervical cancer using genetically engineered lactococci.
Although most immunological studies have been per-
formed with L. lactis producing TTFC and E7 antigen, the
reports supporting the use of recombinant lactococci as
mucosal vaccines continue to grow, and approximately
more than 50 peer-reviewed publications have validated
this potential to date (see additional file 1).
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Cow’s milk allergy (CMA) is a complex disorder and is
the most common allergy in young infants, with an inci-
d e n c er a t eo f2 - 6 % ,d e c r e a s i n gt o0 . 1 - 0 . 5%i na d u l t -
hood. CMA develops early in infancy within 12 to
24 months of birth, but 80-90% of affected children
recover by acquiring tolerance to cow’s milk by the age
of 5 years [29,30]. L. lactis has been engineered to pro-
duce b-lactoglobulin (BLG), one of the major allergens
found in cow’s milk, resulting in LL-BLG. The recombi-
nant BLG was produced predominantly in a soluble,
intracellular, and mostly denatured form. Mucosal
administration of LL-BLG strain induced BLG specific
fecal IgA, although allergen-specific IgE, IgA, IgG1 or
IgG2a were not detected in mice sera [31]. A similar
immune response was reported after oral administration
of recombinant L. lactis secreting a T-cell determinant
IgE epitope of BLG [32]. Adel-Patient et al [33] then
demonstrated that oral administration of recombinant
L. lactis strains producing different amounts of recombi-
nant BLG partially prevents mice from sensitization.
Oral pre-treatment with these strains prevented a Th2-
type immune response elicited by systemic sensitization,
via reduction of specific IgE and the induction of aller-
gen-specific IgG2a and fecal IgA antibodies. The inten-
sity of the Th1 immune response induced correlates
with the amount of recombinant BLG produced, since
t h em o s te f f e c t i v es t r a i n sw e r et h o s ep r o d u c i n gt h e
highest amount of BLG [33].
Similar to oral administration, intranasal delivery of
recombinant L. lactis strains did not induce the secre-
tion of BLG specific antibodies, but elicited IFN-g pro-
duction in murine splenocytes after BLG re-stimulation.
Intranasal pre-treatment of mice with LL-BLG reduced
airway eosinophilia influx and IL-5 secretion in bron-
coalveolar lavage (BAL) after intranasal allergen chal-
lenge. In the same study, intranasal co-administration of
recombinant LL-BLG and LL-IL12 elicited a protective
Th1 immune-response, inhibiting the allergic response
in mice without affecting specific BLG IgE secretion
[34]. Elsewhere, we also showed that intranasal adminis-
tration of LL-IL12 strain decreased allergy symptoms in
an asthma model induced by ovalbumin [35]. The
effects of intranasal administration of LL-BLG strain
were also tested in a therapeutic protocol. In orally sen-
sitized mice, intranasal administration of recombinant
strain reduced IgG1 production but did not influence
specific BLG IgE or IgG2a secretion. After intranasal
challenge, a mild decrease in IL-4 and IL-5 secreted into
BAL was detected [36].
Effects of intranasal administration of recombinant L. lactis
strains secreting human leptin in ob/ob mice
Leptin is a 16 kDa protein encoded by the obese (ob)
gene, and is an adipocyte-derived pleiotropic hormone
that modulates a large number of physiological func-
tions, including control of body weight and regulation of
the immune system [37]. In humans, leptin plays a cru-
cial role in regulation of body weight, as demonstrated
by morbid obesity in patients with congenital mutations
in either leptin or the leptin receptor gene [38-41].
When body fat increases, leptin inhibits food intake and
stimulates energy expenditure to control body weight.
Although leptin treatment induced remarkable weight-
loss in patients with rare congenital leptin deficiency
[42-45], it showed poor efficiency in most obese
patients. Indeed, clinical trials involving subcutaneous
administration of recombinant leptin to obese subjects
indicated that a significant reduction of body weight was
only observed if serum leptin concentrations were 20-
to 30-fold higher than normal physiological levels [46].
This poor response was attributed in part to insufficient
transport of leptin across the blood brain barrier in
obese patients [47].
Since intranasal delivery is an efficient route for admin-
istration of drugs directly to the brain [48-50], we consid-
ered that intranasal leptin administration may be an
interesting strategy to bypass the blood brain barrier in
leptin resistant humans. Thus, the aim of our project was
to measure the effect of intranasal administration of a
recombinant L. lactis strain secreting a biologically active
form of leptin (LL-LEP) in ob/ob mice. We first demon-
strated that the secreted recombinant leptin is a fully bio-
logically active hormone, by showing its capacity to
stimulate a STAT3 reporter gene in HEK293 cells trans-
fected with the Ob-Rb leptin receptor [51]. The immuno-
modulatory activity of the LL-LEP strain was then
evaluated in vivo by co-expression with the L. lactis strain
expressing human papillomavirus type-16 (HPV-16) E7
protein (LL- E7) [51]. In C57BL/6 mice immunized intra-
nasally with LL-LEP and LL-E7 strains, the adaptive
immune response was significantly higher than in mice
immunized with LL-E7 only, demonstrating the adjuvanti-
city of leptin. We then analyzed the effect of daily intrana-
sal administration of LL-LEP in ob/ob mice and thus
observed that this treatment induced a significant reduc-
tion in body weight gain and food intake [51]. These
results demonstrate that leptin can be produced and
secreted in an active form by L. lactis, and that the LL-
LEP strain regulated in vivo antigen-specific immune
responses, as well as body weight and food consumption.
Immune response to antigens delivered by Lactobacillus
spp
The use of genetically modified lactobacilli (i.e. Lb. fermen-
tum, Lb. acidophilus, Lb. casei and Lb. plantarum) to pro-
duce heterologous proteins and to develop a new
generation of mucosal vaccines was first proposed during
the 90s decade [52,53]. By the end of the 90s and into the
early 2000s, several laboratories had successfully utilized
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cles for delivery of medically relevant proteins to mucosal
surfaces, with both strains stimulating strong local immune
responses [6,54]. Approximately 50 peer-reviewed publica-
tions have already been published confirming the advan-
tages of the Lactobacillus genus to serve as live mucosal
vaccines, since lactobacilli can persist longer in the digestive
tract and some strains have probiotic properties (i.e. show
health-promoting activities for humans and animals) [54].
Similar to L. lactis, several studies analyzing the expression
of a variety of viral, bacterial or eukaryotic origin proteins
in Lb. plantarum and Lb. casei have been conducted (see
additional file 1). We have evaluated the immunogenicity of
E7 antigen producing recombinant Lb. plantarum in
mouse models with promising results [55].
Use of recombinant Lb. casei in cow’s milk allergy model
We recently developed a recombinant strain of Lactobacil-
lus casei capable of producing BLG. The immunomodula-
tory potency of intranasal and oral administration of this
recombinant lactobacilli on a subsequent sensitization of
mice to BLG was investigated by Hazebrouck et al. [56],
who analyzed the influence of the administration route on
the immune response elicited by the recombinant BLG Lb.
casei producing strain. Intranasal pre-administration of
the BLG-producing Lb. casei enhanced BLG-specific
IgG2a and IgG1 responses, but did not influence BLG-
specific IgE production in sensitized mice. Unexpectedly,
oral pre-administration led to a significant inhibition of
BLG-specific IgE production, wheras IgG1 and IgG2a
responses were not stimulated in sensitized mice. The pro-
duction of IL-17 by BLG-reactivated splenocytes was simi-
lar between oral and intranasal route administrations.
However in BLG-reactivated splenocytes from mice intra-
nasally pretreated, a greater secretion level of Th1 cyto-
kines (IFN-g and IL-12) and Th2 cytokines (IL-4 and IL-5)
was detected, suggesting a mixed Th1/Th2 cell response;
whereas only production of Th1 cytokines, but not Th2
cytokines, was enhanced in BLG-reactivated splenocytes
from mice orally pretreated. Those results indicate that
the mode of administration of recombinant LAB may be
critical for their immunomodulatory properties [56].
Anti-oxidative proteins delivery by Lb. casei in colitis-
induced murine models
Inflammatory bowel diseases (IBD) constitute a group of
disorders characterized by chronic and relapsing inflam-
mation of the gastrointestinal tract (GIT). The two most
common forms of IBD are Crohn’s disease and ulcerative
colitis, which are associated with an influx of neutrophils
and macrophages, resulting in the consequent production
of inflammatory mediators such as proteases, cytokines
and reactive oxygen species (ROS) [57]. ROS include the
superoxide radical (O2°
-), hydrogen peroxide (H2O2), and
the hydroxyl radical (HO°) [58], which have all been
demonstrated to be both cytotoxic and mutagenic (i.e.
cause damage to cellular lipids, proteins and DNA) [59].
To detoxify ROS, cells have evolved protective mechan-
isms via antioxidant enzymes such as superoxide dismu-
tases (SOD) and catalases (CAT), which degrade O2°
- and
H2O2, respectively, thereby preveningt the formation of
HO° [60]. Thus, therapeutic use of antioxidant enzymes to
decrease ROS amount level is a promising strategy to pre-
vent and/or cure IBD. Several studies have shown that
LAB, such as lactobacilli, may play a preventative role in
IBD [61,62]. Under this context, we originally demon-
strated that Lb. casei BL23 strain can attenuate moderate
Dextran Sodium Sulfate (DSS) induced colitis in mice
[63]. However, the use of a recombinant Lb. casei BL23
strain producing manganese CAT (MnCAT) did not
improve the protective effect of inflammation reduction
[63]. On the other hand, other recent studies have success-
fully reported the use of either recombinant Lb. gasseri or
Lb. plantarum strains to produce and deliver in situ biolo-
gically active manganese SOD (MnSOD) to treat colitis in
an interleukin-10 (IL-10) knockout mouse model and in a
2,4,6-trinitrobenzene sulphonic acid (TNBS)-induced coli-
tis in rats [64][65]. We then cloned MnSOD from Lacto-
coccus lactis into Lb. casei BL23 to evaluate the potential
increase in the aforementioned protective effect towards
ROS by delivery of MnSOD [66]. We therefore compared
the effect of intragastric administration of Lb. casei BL23
MnSOD alone or in combination with Lb. casei BL23
MnCAT in the murine model of DSS 3%-induced colitis.
Based on histological scores, a significant reduction of cae-
cal and colonic inflammation was observed with either
administration of Lb. casei BL23 MnSOD alone or the co-
administration of Lb. casei BL23 MnCAT and Lb. casei
BL23 MnSOD. However, there was no additional improve-
ment in inflammation reduction with the administration
of Lb. casei BL23 MnCAT as compared to administering
Lb. casei BL23 MnSOD alone. These results suggest that
Lb. casei BL23 MnSOD may have an anti-inflammatory
effect on gut inflammation. More recently, we demon-
s t r a t e dt h a tb o t hLb. casei BL23 MnSOD and MnCAT
were able to significantly attenuate TNBS-induced inflam-
mation damage in mice as shown by higher survival rates,
decreased animal weight loss, lower bacterial translocation
to the liver and the prevention of damage to the large
intestine [66].
3. Recombinant lactic acid bacteria as DNA delivery
vehicles
The advantage of DNA vaccines relies in their ability to
induce both cellular and humoral Th1 immune responses
[67,68]. In contrast to bacteria-mediated delivery of pro-
tein antigens, bacteria-mediated delivery of DNA vaccines
leads to the expression of post-translationally modified
antigens by host cells resulting in presentation of confor-
mationally restricted epitopes to the immune system [69].
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and lactobacilli as DNA delivery vehicles is a promising
alternative to attenuated pathogens.
L. lactis is able to modulate the host immune response
through cDNA delivery
Recombinant BLG is expressed mainly in denatured form
with E. coli or L. lactis, whereas its production, in eukaryo-
tic cells, is in the native conformation [31,70]. L. lactis
strains have been used to deliver an expression cassette
encoding BLG cDNA, under the transcriptional control of
the CMV viral promoter, into the Caco-2 epithelial cell
line. The expression cassette was inserted into a L. lactis
replicating plasmid. Production and secretion of BLG was
observed in Caco-2 cells after incubation with L. lactis car-
rying the expression plasmid, demonstrating that non
invasive L. lactis can deliver fully functional plasmids into
epithelial cells. Interestingly, no production of BLG was
observed when Caco-2 cells were co-incubated with puri-
fied plasmid alone or mixed with L. lactis, suggesting that
the plasmid requires to be inside the bacterium in order to
achieve transfer into epithelial cells with subsequent BLG
production [71]. After oral administration of L. lactis in
mice, carrying the eukaryotic expression cassette encoding
for BLG, both BLG cDNA and protein were detected in
the small intestine 72 hours after the final administration.
No BLG (protein/dna or both) was detected 6 days after
the last oral administration. Mice developed a BLG specific
Th1 primary immune response, characterized by a weak
and transitory IgG2a serum response. In sensitized pre-
treated mice, IgE and IL-5 concentrations decreased by
70 and 40%, respectively as compared to sensitized naive
mice. Moreover, only splenocytes from pre-treated mice
secreted IFN-g after BLG specific re-activation [72]. The in
situ production elicits a specific immune response protect-
ing the mice from further sensitization with cow’s milk
proteins. To our knowledge, this is the first evidence of
functional genetic material transfer from food-grade tran-
siting bacteria to a host.
Recombinant invasive lactococci as DNA delivery vehicles
As demonstrated with recombinant E. coli, invasion of the
host cell is a limiting step to achieve efficient DNA vaccine
delivery [73]. To increase lactococcal DNA vaccine deliv-
ery efficiency, L. lactis was rendered invasive by expression
of the inlA gene of Listeria monocytogenes,e n c o d i n gf o r
the Internalin A surface protein, which mediates the inva-
sion of non phagocytic cells by L. monocytogenes[74,75].
Once expressed by L. lactis, InlA can promote the interna-
lization of lactoccocci into the human epithelial line Caco-
2 in vitro and into enterocytes in vivo after oral adminis-
tration to guinea pigs. In addition, L. lactis InlA+ can
deliver a functional plasmid encoding for GFP, and about
1% of Caco-2 cells express GFP after co-culture with this
strain [76]. Recombinant invasive L. lactis strains expres-
sing the Staphylococcus aureus Fibronectin Binding
Protein A encoding gene also showed a heightened ability
to be internalized into mammalian cells as compared to
the control strain. Consequently, both recombinant inva-
sive strains were more efficient in eGFP expression plas-
mid delivery into Caco-2 cells, resulting in a higher
number of GFP producing cells [77]. In vivo, L. lactis InlA
+ was able to invade guinea pig enterocytes after oral
administration [76].
Conclusions and future challenges
We consider that all of our consistent data, together with
those obtained from other groups (see additional file 1),
reinforce the interest in using lactococci and lactobacilli
strains to develop novel therapeutic protein mucosal deliv-
ery vectors, which should be tested now in human clinical
trials. Therefore, a biocontainment strategy to prevent the
dissemination in the environment of these genetically
modified LAB should be developed before they can be
used in humans as it is mentioned in a recent review on
these strategies [78]. Following the demonstration that an
IL-10-producing L. lactis strain (LL-IL10) could treat coli-
tis in mouse models [79], Steidler et al developed the first
biocontainment system for LL-IL10 strain in order to be
allowed to start the first human clinical study using this
recombinant strain. To address these safety concerns with
the use of LL-IL10 in humans, the chromosomal thymidy-
late synthase (thyA) gene was replaced by the gene encod-
ing for IL-10 to generate a thymidine auxotroph
phenotype. In the absence of thymidine or thymine, the
viability of the thyA LL-IL10 strain was reduced by several
orders of magnitude and containment was validated in
vivo in pigs [80]. A phase I clinical trial was then con-
ducted with the thyA LL-IL10 strain in human patients
suffering from CrohnÂ´s disease, demonstrating that the
containment strategy was effective [81]. Following those
positive results, a phase IIA trial was performed and a
press release was published by the end of 2009 revealing
that all three primary endpoints of the study have been
met: i) safety and tolerability; ii) environmental contain-
ment and iii) assessment of biomarkers associated with the
strain. With respect to the secondary endpoint, the clinical
results did not reveal a statistically significant difference in
mucosal healing versus placebo. In view of these results,
the authors of this pioneering human clinical trial and
other teams involved in this promising field should now
consider the optimization of some aspects of their LAB
delivery strategy. The improvement should be done at dif-
ferent levels such as the nature i) of the delivered mole-
cule; ii) of the LAB species as Lb. casei for example seems
to show some advantages compared to L. lactis and iii) of
the expression system to increase the quantities of the
delivered molecule in situ. Such efforts should and need to
be continued because the future of prophylactic and thera-
peutic strategies based on recombinant lactococci and
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Page 6 of 10lactobacilli requires clear demonstration of their efficacy in
such human clinical trials, which will lead to their better
acceptance.
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